WO1988007365A3 - Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic - Google Patents
Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic Download PDFInfo
- Publication number
- WO1988007365A3 WO1988007365A3 PCT/US1988/001096 US8801096W WO8807365A3 WO 1988007365 A3 WO1988007365 A3 WO 1988007365A3 US 8801096 W US8801096 W US 8801096W WO 8807365 A3 WO8807365 A3 WO 8807365A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carrier
- endothelial
- vascular
- diagnostic
- endothelium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3881881T DE3881881T3 (de) | 1987-04-01 | 1988-03-30 | Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe. |
EP88903702A EP0352295B2 (fr) | 1987-04-01 | 1988-03-30 | Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic |
AT88903702T ATE90554T1 (de) | 1987-04-01 | 1988-03-30 | Bioadhaesiver arzneitraeger zur endothelialen und epithelialen aufnahme und laesionalen lokalisierung therapeutischer und diagnostischer stoffe. |
CA000565119A CA1324080C (fr) | 1987-04-01 | 1988-04-26 | Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US033,432 | 1987-04-01 | ||
US07/033,432 US4925678A (en) | 1987-04-01 | 1987-04-01 | Endothelial envelopment drug carriers |
CA000565119A CA1324080C (fr) | 1987-04-01 | 1988-04-26 | Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1988007365A1 WO1988007365A1 (fr) | 1988-10-06 |
WO1988007365A2 WO1988007365A2 (fr) | 1988-10-06 |
WO1988007365A3 true WO1988007365A3 (fr) | 1988-11-17 |
Family
ID=25671864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/001096 WO1988007365A2 (fr) | 1987-04-01 | 1988-03-30 | Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic |
Country Status (8)
Country | Link |
---|---|
US (1) | US4925678A (fr) |
EP (1) | EP0352295B2 (fr) |
JP (1) | JP2886171B2 (fr) |
AT (1) | ATE90554T1 (fr) |
AU (1) | AU607494B2 (fr) |
CA (1) | CA1324080C (fr) |
DE (1) | DE3881881T3 (fr) |
WO (1) | WO1988007365A2 (fr) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
US5807832A (en) * | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
EP0361960A3 (fr) * | 1988-09-29 | 1992-01-02 | RANNEY, David F. | Procédé et compositions pour la production d'images par résonance magnétique |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
US5260050A (en) * | 1988-09-29 | 1993-11-09 | Ranney David F | Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
CA2069635C (fr) * | 1989-11-27 | 1998-05-05 | Junzo Seki | Emulsion de matieres grasses |
US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
IN172208B (fr) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US6989141B2 (en) | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US7083778B2 (en) | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
BR9106377A (pt) * | 1990-04-26 | 1993-04-27 | Cytrx Corp | Composicao e processo para o tratamento topico de tecido lesado ou enfermo |
US5216130A (en) * | 1990-05-17 | 1993-06-01 | Albany Medical College | Complex for in-vivo target localization |
AU707085B2 (en) * | 1991-04-02 | 1999-07-01 | Access Pharmaceuticals Australia Pty Limited | Oral delivery systems for microparticles |
CA2084194C (fr) * | 1991-04-02 | 2003-05-20 | Gregory John Russell-Jones | Systeme de liberation orale pour microparticules |
US5705178A (en) * | 1991-05-31 | 1998-01-06 | Gliatech, Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
GB9119762D0 (en) * | 1991-09-16 | 1991-10-30 | Filler Aaron G | Particulate agents for nmt |
IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
FR2687071B1 (fr) * | 1992-02-10 | 1995-06-23 | Exsymol Sa | Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur. |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
WO1994002183A1 (fr) * | 1992-07-27 | 1994-02-03 | Haemacure Biotech Inc. | Implant chirurgical biocompatible |
JP3337075B2 (ja) * | 1992-08-05 | 2002-10-21 | 名糖産業株式会社 | 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体 |
ATE198268T1 (de) * | 1992-10-08 | 2001-01-15 | Supratek Pharma Inc | Zusammensetzung von in mizellen eingeschlossenen antineoplastischen wirkstoffen |
US5362425A (en) * | 1992-10-22 | 1994-11-08 | Technology Unlimited, Inc. | Organic oil spray-drying techniques |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
WO1994018955A1 (fr) * | 1993-02-22 | 1994-09-01 | Alza Corporation | Compositions destinees a l'apport oral d'agents actifs |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
JP3746293B2 (ja) * | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | 生物製剤のインビボ送達の方法とそのための組成物 |
JPH08508721A (ja) * | 1993-03-17 | 1996-09-17 | シリカゲル ゲス.エム.ビー.エイチ | 超常磁性粒子、その製法及びその用途 |
GB9312315D0 (en) * | 1993-06-15 | 1993-07-28 | Poston Robin | Leukocyte adhesion assay |
EP0636363B1 (fr) * | 1993-07-27 | 2001-05-23 | Terumo Kabushiki Kaisha | Système pour la délivrance d'un médicament |
ES2231775T5 (es) | 1993-07-30 | 2011-02-02 | Imcor Pharmaceutical Co. | Composición de microburbujas estabilizadas para ecografía. |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
US5633003A (en) * | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
AUPM572294A0 (en) * | 1994-05-18 | 1994-06-09 | Vaccine Technologies Pty. Ltd. | Delivery vehicle for bioactive molecule |
WO1996004922A1 (fr) * | 1994-08-10 | 1996-02-22 | Davis, Joanne, T. | Methode d'utilisation de l'acide hyaluronique pour la detection, la localisation et le diagnostic de tumeurs |
FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US6107102A (en) * | 1995-06-07 | 2000-08-22 | Regents Of The University Of California | Therapeutic microdevices and methods of making and using same |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
JPH11507913A (ja) * | 1995-06-07 | 1999-07-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療用マイクロデバイスならびにその製造方法および使用方法 |
US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
CA2235036A1 (fr) | 1995-11-08 | 1997-05-15 | University Of South Florida | Systeme d'experimentation de leiomyome et d'atherosclerose sur des cobayes |
AU716667B2 (en) | 1996-01-10 | 2000-03-02 | Nycomed Imaging As | Contrast media |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
US5855868A (en) * | 1996-04-01 | 1999-01-05 | Nycomed Imaging As | Method of T1 -weighted resonance imaging of RES organs |
EP0954326B2 (fr) | 1996-04-19 | 2009-07-22 | Grifols Inc. | Procede d'inactivation de virus dans des proteines sanguines lyophilisees |
EP1369111A1 (fr) * | 1996-10-03 | 2003-12-10 | Hermes Biosciences, Inc. | Microparticules hydrophiles et leurs procédés de préparation |
US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
ES2355186T3 (es) * | 1997-09-05 | 2011-03-23 | Maruho K.K. | Preparaciones de nanocápsulas para tratar enfermedades intraarticulares. |
US6489306B2 (en) | 1998-02-23 | 2002-12-03 | University Of South Florida | Method of intranasal gene transfer for protection against respiratory infection |
US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
US6338834B1 (en) | 1998-04-30 | 2002-01-15 | The Curators Of The University Of Missouri | Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma |
US6391861B1 (en) | 1998-05-14 | 2002-05-21 | The Trustees Of Columbia University In The City Of New York | Method for the prevention of tissue elastic fiber injury |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
AU4994899A (en) | 1998-07-13 | 2000-02-01 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
AU5329599A (en) * | 1998-07-30 | 2000-02-21 | University Of South Florida | Method for the modulation of function of transcription factors |
US6780397B2 (en) | 1998-09-01 | 2004-08-24 | Curators Of The University Of Missouri | Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents |
US6379691B1 (en) | 1998-09-29 | 2002-04-30 | Medtronic/Ave, Inc. | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US6299980B1 (en) | 1998-09-29 | 2001-10-09 | Medtronic Ave, Inc. | One step lubricious coating |
US6409987B1 (en) | 1999-04-07 | 2002-06-25 | Intimax Corporation | Targeted agents useful for diagnostic and therapeutic applications |
US6638974B1 (en) | 1999-04-09 | 2003-10-28 | University Of South Florida | Ascorbyl esters for the treatment of cancer |
US6787318B1 (en) | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
ES2313895T3 (es) * | 1999-06-14 | 2009-03-16 | Henry Ford Health System | Donadores de oxido nitrico para inducir neurogenesis. |
US7135498B1 (en) | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
US7655423B2 (en) * | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
AU4710401A (en) | 1999-12-02 | 2001-06-18 | University Of South Florida | Method and composition for treatment of ischemic neuronal reperfusion injury |
WO2001093846A2 (fr) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Procede de traitement des troubles respiratoires associes a une lesion de la fibre elastique pulmonaire |
AU2002218744A1 (en) * | 2000-07-11 | 2002-01-21 | University Of South Florida | Bax fragment induced tumor cell death |
US6803060B2 (en) | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
US20060194242A1 (en) * | 2000-10-27 | 2006-08-31 | Hadden John W | Immunotherapy for immune suppressed patients |
US20070031372A1 (en) * | 2004-08-05 | 2007-02-08 | Hadden John W | Vaccine immunotherapy for immune suppressed patients |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
JP2004521867A (ja) * | 2000-10-27 | 2004-07-22 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制された患者のためのワクチン免疫療法 |
US7182942B2 (en) * | 2000-10-27 | 2007-02-27 | Irx Therapeutics, Inc. | Vaccine immunotherapy for immune suppressed patients |
US20020146409A1 (en) * | 2001-01-30 | 2002-10-10 | Herring Steven W. | Methods for stabilizing lyophilized blood proteins |
US7172770B2 (en) * | 2001-02-19 | 2007-02-06 | Board Of Regents, The University Of Texas System | Mesoporous compositions for use in drug delivery |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
JP2005510491A (ja) | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
EP1389487B1 (fr) * | 2002-07-16 | 2006-05-03 | Seiko Epson Corporation | Composition contenant des microcapsules pour écrans électrophorétiques |
AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
US20050049196A1 (en) * | 2003-08-29 | 2005-03-03 | Michael Hutchinson | Indirect delivery of growth factors into the central nervous system |
WO2005034980A1 (fr) * | 2003-09-12 | 2005-04-21 | University Of Colorado | Glutamine pour le traitement de lesion |
WO2005059100A2 (fr) * | 2003-12-12 | 2005-06-30 | New York University | Procedes et compositions se rapportant a la cystatine c |
DE602005025347D1 (de) | 2004-01-30 | 2011-01-27 | Quark Pharmaceuticals Inc | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten |
AP2007003921A0 (en) | 2004-08-16 | 2007-02-28 | Atugen Ag | Therapeutic uses of inhibitors of rtp801 |
JPWO2006035550A1 (ja) * | 2004-09-28 | 2008-05-15 | 国立大学法人大阪大学 | 三次元誘導装置及び方法、並びに薬剤配送システム |
ES2594083T3 (es) | 2004-09-28 | 2016-12-15 | Quark Pharmaceuticals, Inc. | Oligorribonucleótidos y métodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades |
US8541177B2 (en) | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
NL2000439C2 (nl) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
US20080260678A1 (en) * | 2006-10-10 | 2008-10-23 | University Of Colorado | Molecular band-aid |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
US8729121B2 (en) * | 2007-06-25 | 2014-05-20 | Adhezion Biomedical, Llc | Curing accelerator and method of making |
US8785408B2 (en) | 2007-06-27 | 2014-07-22 | Quark Pharmaceuticals, Inc. | Compositions and methods for reducing or protecting against delayed graft function (DGF) |
US8614309B2 (en) | 2007-10-03 | 2013-12-24 | Quark Pharmaceuticals, Inc. | Double-stranded RNA directed to CASP2 and methods of use thereof |
WO2009064291A1 (fr) * | 2007-11-14 | 2009-05-22 | Spartan Medical Products, Llc | Colles tissulaires à base de cyanoacrylate |
US8486528B2 (en) * | 2008-01-22 | 2013-07-16 | Gwangju Institute Of Science And Technology | Temperature-sensitive nano-carriers |
EP2106791A1 (fr) | 2008-03-31 | 2009-10-07 | Biotempt B.V. | Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations |
US8198344B2 (en) * | 2008-06-20 | 2012-06-12 | Adhezion Biomedical, Llc | Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator |
US8293838B2 (en) * | 2008-06-20 | 2012-10-23 | Adhezion Biomedical, Llc | Stable and sterile tissue adhesive composition with a controlled high viscosity |
US20110117047A1 (en) | 2008-06-23 | 2011-05-19 | Adhezion Biomedical, Llc | Cyanoacrylate tissue adhesives with desirable permeability and tensile strength |
US8652510B2 (en) | 2008-10-31 | 2014-02-18 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
US9254133B2 (en) | 2008-10-31 | 2016-02-09 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
US8609128B2 (en) * | 2008-10-31 | 2013-12-17 | Adhezion Biomedical, Llc | Cyanoacrylate-based liquid microbial sealant drape |
US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
WO2010111598A1 (fr) | 2009-03-26 | 2010-09-30 | Henry Ford Health System | Procédés pour améliorer l'évolution neurologique après une lésion neurale et une maladie neurodégénérative |
EP2440214A4 (fr) | 2009-06-08 | 2013-07-31 | Quark Pharmaceuticals Inc | Procédés de traitement de maladie rénale chronique |
JP2013511990A (ja) | 2009-11-26 | 2013-04-11 | クォーク ファーマシューティカルズ インコーポレーティッド | 末端置換を含むsiRNA化合物 |
US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
KR101692063B1 (ko) | 2009-12-09 | 2017-01-03 | 닛토덴코 가부시키가이샤 | hsp47 발현의 조절 |
WO2011084193A1 (fr) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques |
US9486005B2 (en) | 2010-02-22 | 2016-11-08 | Smiti Vaid Gupta | Agents and mechanisms for treating hypercholesterolemia |
US9309019B2 (en) | 2010-05-21 | 2016-04-12 | Adhezion Biomedical, Llc | Low dose gamma sterilization of liquid adhesives |
KR101553753B1 (ko) | 2010-06-24 | 2015-09-16 | 쿠아크 파마수티칼스 인코퍼레이티드 | Rhoa에 대한 이중 가닥 rna 및 그의 용도 |
US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
CA2818024C (fr) | 2010-12-06 | 2019-09-24 | Quark Pharmaceuticals, Inc. | Composes oligonucleotidiques a double brin comprenant des modifications de position |
US9487778B2 (en) | 2011-03-03 | 2016-11-08 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
CA2828002A1 (fr) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions et procedes pour traiter des maladies et des lesions pulmonaires |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
EP2797632A1 (fr) | 2012-01-01 | 2014-11-05 | QBI Enterprises Ltd. | Particules ciblant endo180 pour l'administration sélective d'agents thérapeutiques et diagnostiques |
CA2858630A1 (fr) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Polytherapie destinee au traitement de troubles de l'audition et de l'equilibre |
WO2013173923A1 (fr) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations de kallikréine 1 de tissu humain pour l'administration parentérale et procédés associés |
HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
ES2651113T3 (es) | 2012-06-25 | 2018-01-24 | The Brigham And Women's Hospital, Inc. | Tratamientos terapéuticos dirigidos |
US9611474B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof |
WO2014043291A1 (fr) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Composés d'acide nucléique double brin |
WO2014043292A1 (fr) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Molécules d'oligonucléotide à double brin p53 et procédés d'utilisation correspondants |
EP2934540B1 (fr) | 2012-12-24 | 2023-08-02 | Neurogastrx, Inc. | Méthodes de traitement d'affections du tractus digestif |
BR112015022181A8 (pt) | 2013-03-12 | 2018-01-23 | Massachusetts Eye & Ear Infirmary | proteínas da substância de inibição mulleriana (mis) e usos das mesmas para o tratamento de doenças |
US9539265B2 (en) | 2013-03-15 | 2017-01-10 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
WO2014142938A1 (fr) * | 2013-03-15 | 2014-09-18 | Aihol Corporation | Formulation pharmaceutique contenant un glycosaminoglycane |
WO2014201372A1 (fr) | 2013-06-13 | 2014-12-18 | Health Enhancement Products, Inc. | Composés et procédés pour affecter la sécrétion des cytokines |
WO2015020960A1 (fr) | 2013-08-09 | 2015-02-12 | Novartis Ag | Nouveaux polynucléotides longs arn non codants (arn lnc) |
AU2014362307A1 (en) | 2013-12-11 | 2016-06-30 | The General Hospital Corporation | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation |
US9421297B2 (en) | 2014-04-02 | 2016-08-23 | Adhezion Biomedical, Llc | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides |
US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
WO2016133922A1 (fr) | 2015-02-16 | 2016-08-25 | Zivo Bioscience, Inc. | Procédés de modulation de réponses immunitaires et inflammatoires par le biais de l'administration d'une biomasse algale |
MX2018009819A (es) | 2016-02-16 | 2019-02-20 | Zivo Bioscience Inc | Soporte nutricional para animales mediante la administracion de un suplemento derivado de algas. |
CA3054962A1 (fr) | 2017-03-09 | 2018-09-13 | Rick PAULS | Formes posologiques de kallicreine tissulaire 1 |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
EP3922720A1 (fr) | 2020-06-09 | 2021-12-15 | Universidad de Murcia | Thérapie pour empêcher un remodelage cardiaque indésirable après un infarctus aigu du myocarde |
US20220265582A1 (en) | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
US11801256B2 (en) | 2021-06-08 | 2023-10-31 | Universitätsspital Basel | Antidepressant-psilocybin co-treatment to assist psychotherapy |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1516348A (en) * | 1974-09-18 | 1978-07-05 | Pharma Soc Of Victoria | Injectable compositions |
GB2041517A (en) * | 1979-01-09 | 1980-09-10 | Fuji Photo Film Co Ltd | Material and process for immunological assay |
EP0087786A1 (fr) * | 1982-02-28 | 1983-09-07 | Yeda Research And Development Company, Ltd. | Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage |
CA1168150A (fr) * | 1981-12-18 | 1984-05-29 | The Governors Of The University Of Alberta | Conjugats d'albumine et d'agents therapeutiques |
EP0167825A2 (fr) * | 1984-06-08 | 1986-01-15 | Dr. Rentschler Arzneimittel GmbH & Co. | Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
EP0240424A1 (fr) * | 1986-03-28 | 1987-10-07 | Universite De Rennes I | Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2374910A1 (fr) * | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US4182330A (en) * | 1977-07-25 | 1980-01-08 | Alza Corporation | Means for administering amphipathic medicament |
CS216992B1 (en) * | 1980-07-21 | 1982-12-31 | Miroslav Stol | Composite polymere material for the biological and medicinal utilitation and method of preparation thereof |
JPS57130914A (en) * | 1981-02-04 | 1982-08-13 | Agency Of Ind Science & Technol | Prolongation of activity retention |
SE8204244L (sv) * | 1982-07-09 | 1984-01-10 | Ulf Schroder | Kristalliserad kolhydratsmatris for biologiskt aktiva substanser |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
SE8201972L (sv) * | 1982-03-29 | 1983-09-30 | Gambro Lundia Ab | Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material |
US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
US4568536A (en) * | 1985-02-08 | 1986-02-04 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
-
1987
- 1987-04-01 US US07/033,432 patent/US4925678A/en not_active Expired - Lifetime
-
1988
- 1988-03-30 WO PCT/US1988/001096 patent/WO1988007365A2/fr active IP Right Grant
- 1988-03-30 DE DE3881881T patent/DE3881881T3/de not_active Expired - Fee Related
- 1988-03-30 JP JP63503579A patent/JP2886171B2/ja not_active Expired - Fee Related
- 1988-03-30 AU AU16275/88A patent/AU607494B2/en not_active Ceased
- 1988-03-30 AT AT88903702T patent/ATE90554T1/de not_active IP Right Cessation
- 1988-03-30 EP EP88903702A patent/EP0352295B2/fr not_active Expired - Lifetime
- 1988-04-26 CA CA000565119A patent/CA1324080C/fr not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1516348A (en) * | 1974-09-18 | 1978-07-05 | Pharma Soc Of Victoria | Injectable compositions |
GB2041517A (en) * | 1979-01-09 | 1980-09-10 | Fuji Photo Film Co Ltd | Material and process for immunological assay |
CA1168150A (fr) * | 1981-12-18 | 1984-05-29 | The Governors Of The University Of Alberta | Conjugats d'albumine et d'agents therapeutiques |
EP0087786A1 (fr) * | 1982-02-28 | 1983-09-07 | Yeda Research And Development Company, Ltd. | Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage |
EP0167825A2 (fr) * | 1984-06-08 | 1986-01-15 | Dr. Rentschler Arzneimittel GmbH & Co. | Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
EP0240424A1 (fr) * | 1986-03-28 | 1987-10-07 | Universite De Rennes I | Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament |
Also Published As
Publication number | Publication date |
---|---|
DE3881881T2 (de) | 1993-12-16 |
EP0352295A1 (fr) | 1990-01-31 |
EP0352295B2 (fr) | 1996-04-10 |
DE3881881T3 (de) | 1997-06-05 |
US4925678A (en) | 1990-05-15 |
CA1324080C (fr) | 1993-11-09 |
AU1627588A (en) | 1988-11-02 |
ATE90554T1 (de) | 1993-07-15 |
JPH04504404A (ja) | 1992-08-06 |
JP2886171B2 (ja) | 1999-04-26 |
AU607494B2 (en) | 1991-03-07 |
DE3881881D1 (de) | 1993-07-22 |
EP0352295B1 (fr) | 1993-06-16 |
WO1988007365A2 (fr) | 1988-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1988007365A3 (fr) | Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic | |
US5814599A (en) | Transdermal delivery of encapsulated drugs | |
ES2056832T3 (es) | Un vehiculo de liberacion para un ingrediente activo. | |
DE69010336D1 (de) | Pharmazeutische zusammensetzung zum abnehmen. | |
CA2628857A1 (fr) | Preparation et methode de traitement de neoplasmes par inhalation | |
CO5261582A1 (es) | Composiciones de valdecoxib | |
Parsons et al. | Initial fall of plasma calcium after intravenous injection of parathyroid hormone | |
CA2382143A1 (fr) | Procede, reactif et cartouche d'essai destines a determiner le temps de coagulation | |
EP2298310A3 (fr) | Inhibiteur thérapeutique de cellules de muscles vasculaires lisses | |
Taal et al. | Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice | |
SK42395A3 (en) | Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof | |
Brindley et al. | Studies of the Pharmacology of N-Methylformamide in Miceš, 2 | |
Jewell et al. | Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis | |
Mansell et al. | The in vivo destruction of human tumor by glucan activated macrophages | |
Pattanapanyasat et al. | Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function | |
Cartwright | Use of antibiotics. Antifungals. | |
JP4116075B2 (ja) | β―インターフェロンを使用して再狭窄を治療する方法 | |
Lupera et al. | Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer | |
Ernst et al. | In vitro susceptibility testing and the outcome of treatment of infection. | |
McCue et al. | A proposed short form of the Luria-Nebraska Neuropsychological Battery oriented toward assessment of the elderly. | |
Hoehne et al. | Comparison of epinephrine excretion after aerosol and subcutaneous administration | |
Shah et al. | Development and clinical evaluation of a verapamil transdermal delivery system | |
Brunschwig et al. | The secretion of chlorine ions in achlorhydric gastric juice: Observations by means of radioactive chlorine | |
DE69724228D1 (de) | Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten | |
Kottmeier | Increased dosage requirement of gentamicin in burn patients: DE Zaske, RJ Sawchuk, DN Gerding, and RG Strate. J Trauma 16: 824–828, 1976 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988903702 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988903702 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1988903702 Country of ref document: EP |